A5085474533- Colorectal Cancer Treatments and Studies
- Statistical Methods in Clinical Trials
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Surgical Treatments
- Advanced Causal Inference Techniques
- Advanced Breast Cancer Therapies
- Genetic factors in colorectal cancer
- Meta-analysis and systematic reviews
- Colorectal and Anal Carcinomas
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Screening and Detection
- Statistical Methods and Inference
- Pancreatic and Hepatic Oncology Research
- Prostate Cancer Treatment and Research
- Monoclonal and Polyclonal Antibodies Research
- Radiomics and Machine Learning in Medical Imaging
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Gene expression and cancer classification
International Drug Development Institute (Belgium)
2016-2025
Hasselt University
2016-2025
Institut des Arts de Diffusion
2009-2025
International Drug Development
2010-2024
University College London
2009-2024
Northwestern University
2024
Christus Health
2024
Duke University
2024
Clinique Saint Jean
2003-2023
Centre Jean Bernard
2003-2023
In metastatic colorectal cancer, phase III studies have demonstrated the superiority of fluorouracil (FU) with leucovorin (LV) in combination irinotecan or oxaliplatin over FU + LV alone. This study investigated two sequences: folinic acid, FU, and (FOLFIRI) followed by (FOLFOX6; arm A), FOLFOX6 FOLFIRI (arm B).
Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated cardiac toxicity. We wanted to evaluate efficacy and safety a new nonanthracycline regimen trastuzumab.We randomly assigned 3222 women HER2-positive early-stage cancer receive doxorubicin cyclophosphamide followed by docetaxel every 3 weeks (AC-T), same plus 52 trastuzumab (AC-T trastuzumab), or carboplatin (TCH). The primary...
Background: Histologic grade in breast cancer provides clinically important prognostic information. However, 30%–60% of tumors are classified as histologic 2. This is associated with an intermediate risk recurrence and thus not informative for clinical decision making. We examined whether was gene expression profiles cancers such could be used to improve grading. Methods: analyzed microarray data from 189 invasive carcinomas three published datasets carcinomas. identified differentially...
A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal validate the an independent group of patients.Patients (n = 307, 137 events after a median follow-up 13.6 years) from five European centers were divided into high- and low-risk groups based on gene classification clinical risk classifications. Patients assigned if their 5-year distant metastasis-free survival probability as estimated by greater than 90%. clinicopathologic...
Abstract Purpose: Recently, a 76-gene prognostic signature able to predict distant metastases in lymph node–negative (N−) breast cancer patients was reported. The aims of this study conducted by TRANSBIG were independently validate these results and compare the outcome with clinical risk assessment. Experimental Design: Gene expression profiling frozen samples from 198 N− systemically untreated done at Bordet Institute, blinded data independent Veridex. Genomic defined Veridex, data....
A number of microarray studies have reported distinct molecular profiles breast cancers (BC), such as basal-like, ErbB2-like, and two to three luminal-like subtypes. These were associated with different clinical outcomes. However, although the basal ErbB2 subtypes are repeatedly recognized, identification estrogen receptor (ER) -positive has been inconsistent. Therefore, refinement their definition is needed.We previously a gene expression grade index (GGI), which defines histologic based on...
In metastatic colorectal cancer, a combination of leucovorin (LV) and fluorouracil (FU) with oxaliplatin (FOLFOX) 4 is standard first-line regimen. The cumulative neurotoxicity often requires therapy to be stopped in patients who are still responding. This study evaluates new strategy intermittent treatment that based on FOLFOX7, simplified regimen high-dose oxaliplatin.Previously untreated were randomly assigned either FOLFOX4 administered every 2 weeks until progression (arm A) or FOLFOX7...
Purpose A traditional end point for colon adjuvant clinical trials is overall survival (OS), with 5 years demonstrating adequate follow-up. shorter-term providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice. Methods Individual patient data were pooled from 18 randomized phase III cancer trials. Trials included 43 arms, a sample size 20,898 patients. The primary hypothesis was that disease-free (DFS), 3 follow-up, an...
A randomized clinical trial was conducted by the European Organization for Research and Treatment Cancer (EORTC) Gastrointestinal Cooperative Group to study effectiveness of irradiation therapy administered in a dosage 34.5 Gy, divided into 15 daily doses 2.3 Gy each before radical surgery rectal cancer (T2, T3, T4, NX, MO). Four hundred sixty-six patients were entered between June 1976 September 1981. Tolerance side effects pre- operative acceptable. The overall 5-year survival rates...
Limited data are available on the time course of treatment failures (recurrence and/or death), nature and duration adjuvant benefit, long-term recurrence rates in patients with resected stage II III colon cancer.
van der Burg, Maria E. L.; Lent, Mat; Buyse, Marc; Kobierska, Ann; Colombo, Nicoletta; Favalli, Giuseppe; Lacave, Angel J.; Nardi, Mario; Renard, Josette; Pecorelli, Sergio Author Information
To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma.Patients HER2-positive adenocarcinoma were randomly assigned at a one-to-one ratio CapeOx plus 1,250 mg or placebo daily. Primary end point was overall survival (OS) centrally confirmed HER2 amplification primary population.A total 545 assigned, 487 comprised population....
Abstract Background: Evaluation of the long-term benefit biologically-based regimens trastuzumab in early breast cancer population, and optimization integration to maximize efficacy minimize cardiac toxicity.Material Methods: We randomized HER2-positive (FISH+) patients with axillary lymph node positive or high risk negative, either standard AC (60/600 mg/m2 q3wk x4) followed by T (100 x 4) two trastuzumab-containing regimens; 1 year TCarbo (75 mg/m2/AUC6 6) year. Patients were prospectively...
The validation of surrogate endpoints has been studied by Prentice (1989). He presented a definition as well set criteria, which are equivalent only if the and true binary. Freedman et al. (1992) supplemented these criteria with so-called 'proportion explained'. Buyse Molenberghs (1998) proposed replacing proportion explained two quantities: (1) relative effect linking treatment on both (2) an individual-level measure agreement between endpoints. latter quantity carries over when data...